Results 91 to 100 of about 16,846 (200)

Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells [PDF]

, 2014
ABT-737 inhibits the anti-apoptotic proteins B-cell lymphoma 2 (BCL-2) and BCL-X L. Meayamycin B switches the splicing pattern of myeloid cell leukemia factor 1 (MCL1) pre-mRNA.
Ferris, RL, Gao, Y, Koide, K, Trivedi, S
core   +2 more sources

Co‐Mutation of ASXL1 and KRAS Defines a Novel Ultra‐Adverse‐Risk Subtype of Acute Myeloid Leukemia in a Large‐Scale Cohort

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Background ASXL1 mutation acute myeloid leukemia represents a clinically aggressive subtype with heterogeneous outcomes. Current evidence remains inconclusive regarding the prognostic relevance of the KRAS mutation partner in AML with ASXL1 mutation.
Yijing Zhao, Ting Zhao, Feifei Tang, Xiaodong Mo, Yingjun Chang, Xiaosu Zhao, Lanping Xu, Yu Wang, Xiaohui Zhang, Hao Jiang, Qian Jiang, Xiaojun Huang, Yuqian Sun   +12 more
wiley   +1 more source

Advancing the therapeutic effectiveness of paclitaxel in chronic lymphocytic leukemia through the simultaneous inhibition of NOTCH1 and SF3B1

Cancer Cell International
Background Chemoresistance is still a significant obstacle to cancer therapy. Overexpression of the splicing factor 3b subunit 1 (SF3B1) and neurogenic locus notch homolog protein 1 (NOTCH1) factors is typically found in chronic lymphocytic leukemia (CLL)
Shiva Abolhasani, Armin Mahmoud salehi Khesht, Atefeh Khodakarami, Ali Masjedi, Bentolhoda Rashidi, Sepideh Izadi, Fatemeh Karimian Noukabadi, Vahid Karpisheh, Khatereh Torabi Poudeh, Pooya Jalali, Zahra Salehi, Rafieh Bagherifar, Seyyed Sina Hejazian, AliAkbar Movassaghpour, Abbas Ali Hosseinpour Feizi, Farhad Jadidi   +15 more
doaj   +1 more source

Allele Loss and Reduced Expression of CYCLOPS Genes is a Characteristic Feature of Chromophobe Renal Cell Carcinoma

Translational Oncology, 2019
Copy-number alterations Yielding Cancer Liabilities Owing to Partial losS (CYCLOPS) genes have been recently identified as the most enriched class of copy-number associated gene dependencies in human cancer.
Riuko Ohashi, Peter Schraml, Aashil Batavia, Silvia Angori, Patrik Simmler, Niels Rupp, Yoichi Ajioka, Esther Oliva, Holger Moch   +8 more
doaj   +1 more source

Mutational landscape of RNA-binding proteins in human cancers [PDF]

, 2017
RNA Binding Proteins (RBPs) are a class of post-transcriptional regulatory molecules which are increasingly documented to be dysfunctional in cancer genomes. However, our current understanding of these alterations is limited.
Bhat-Nakshatri, Poornima, Gonzalez-Perez, Abel, Janga, Sarath Chandra, Nakshatri, Harikrishna, Neelamraju, Yaseswini   +4 more
core   +2 more sources

Depletion of the MFAP1/SPP381 Splicing Factor Causes R-Loop-Independent Genome Instability [PDF]

, 2019
THO/TREX is a conserved complex with a role in messenger ribonucleoprotein biogenesis that links gene expression and genome instability. Here, we show that human THO interacts with MFAP1 (microfibrillar-associated protein 1), a spliceosome-associated ...
Aguilera López, Andrés, Andújar, Eloísa, Barroso Ceballos, Sonia Inés, García Rondón, Ana, Luna Varo, Rosa María, Pérez Calero, Mónica, Salas Armenteros, Irene   +6 more
core   +1 more source

Analysis of SF3B1 mutations in monoclonal B‐cell lymphocytosis [PDF]

Hematological Oncology, 2012
[No abstract available]
Mariangela Greco, Daniela Capello, Alessio Bruscaggin, Valeria Spina, Silvia Rasi, Sara Monti, Carmela Ciardullo, Stefania Cresta, Marco Fangazio, Gianluca Gaidano, FOA, Roberto, Davide Rossi   +11 more
openaire   +4 more sources

Response to therapy and prognosis according to molecular characterization in CALR‐mutated essential thrombocythemia

HemaSphere, Volume 10, Issue 3, March 2026.
Abstract Response to cytoreductive therapy according to CALR mutation type, CALR variant allele frequency (VAF), and additional mutations has not been previously studied in essential thrombocythemia (ET). The impact of the molecular profile on treatment response and the main clinical outcomes was analyzed in 557 CALR ET patients (CALR Type 1, n = 339 ...
Marta Santaliestra, Marta Garrote, María Concepción Fernández‐Rodríguez, Patricia Vélez, Alicia Senín, Eduardo Arellano‐Rodrigo, Neus Garcia‐Gisbert, Raquel Longarón, Manuel Pérez‐Encinas, Gonzalo Caballero‐Navarro, Maria Soledad Noya‐Pereira, Beatriz Cuevas, María Teresa Gómez‐Casares, Ruth Stuckey, Gonzalo Carreño‐Tarragona, Francisca Ferrer‐Marin, Miguel Angel Cortés, Elena Magro, Isabel Mata, Anna Angona, Raúl Pérez, María Laura Fox, Irene Pastor‐Galán, Paula Sastre, Ana Triguero, Valentín García‐Gutierrez, Juan Carlos Hernández‐Boluda, Beatriz Bellosillo, Alberto Alvarez‐Larran   +28 more
wiley   +1 more source

Targeted therapy and outcome in chronic lymphocytic leukemia [PDF]

, 2014
Despite major advances, chronic lymphocytic leukemia (CLL) is still considered incurable. Fludarabine refractory patients and those with TP53disruptions have a particularly poor prognosis.
Eketorp Sylvan, Sandra
core   +1 more source

Ageing Through the Looking‐Glass: The Different Flavours of Clonal Haematopoiesis

Aging Cell, Volume 25, Issue 3, March 2026.
Different forms of CH share common germline and environmental risk factors and have overlapping prevalence and disease associations, suggesting common underlying ageing processes. We explore intersections of different forms of CH, clinical implications of these, and how this enhances our understanding of the biology of ageing.
Jasmine Singh, David J. Curtis, Le Thi Phuong Thao, Erica M. Wood, Zoe K. McQuilten   +4 more
wiley   +1 more source